More than 95% of patients with VHL disease will have a detectable VHL gene mutation and well-defined genotype–phenotype mean that the nature of the mutation may predict likely tumour risks (e.g. risk of phaeochromocytoma is small with truncating mutations and exonic deletions) [3, 5]. The gene discussed is VHL; the disease is pheochromocytoma.